Copeland's Dickson buy adds cloud-native monitoring as the pharma cold chain moves toward continuous visibility to meet rising regulatory demands.
|Articles|June 10, 2022
- Pharmaceutical Commerce - June 2022
- Volume 17
- Issue 3
Pharmaceutical Commerce - June 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Commerce June 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 4 years ago
Food for Thought from Franceover 4 years ago
The Impact of War on Drug Supply Chainover 4 years ago
Controlling Diabetes: Advances & Adherenceover 4 years ago
The Promise of Industry 4.0over 4 years ago
From Point-in-time to Real-timeover 4 years ago
Dealing with Dangerous Goodsover 4 years ago
Countdown to 2023 DSCSA Complianceover 4 years ago
The Key Steps Ahead of DSCSA D-Dayover 4 years ago
New Serialization Mandates Inch Closerover 4 years ago
Closing a Key Gap in DSCSA ComplianceAdvertisement
Related to this article
In this week's Pharma Pulse, Vicapsys merges with Stateline, Veritiv targets GLP-1 shipping, Section 232 tariffs widen and HRSA's 340B rebate pilot deadline arrives.
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
Cencora's Ameer Ali on the operational lift behind the 12-digit NDC shift, the readiness gap across manufacturers and what's at stake for product flow if systems aren't ready in time.
Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s and cell and gene therapies raise cold chain stakes.
Valerie Bandy of Tecsys on where 340B rebate mechanics threaten pharmacy purchasing, and how stakeholders can prevent disruption.
CMS says 40 states and Puerto Rico have signed on to the GENEROUS Model, which applies MFN pricing to Medicaid drugs through state-invoiced rebates.
Informa's invitation-only Leadership Summit returns to CPHI Milan Oct. 6 as executives weigh sourcing, medicine security and reshoring pressure.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
FAQ: How the GENEROUS Model Applies MFN Pricing to Medicaid
2
Supply Chain Signal: How Policy Pressures Are Converging on Pharma
3
Why Temperature Control Is Now Pharma’s Make-or-Break Variable
4
Pharma Pulse: Vicapsys-Stateline Merger and Veritiv's TempSafe RxShield
5